3 tracked public figures made calls on RLAY.
Every pick graded against the S&P 500 over matching windows.
Total Calls
4
4 buy · 0 sell
Avg Buy Return
+99.0%
vs S&P +8.2%
Best Buy Call
+268.2%
Scott Minerd · Sep 2025
Figures Tracked
3
public figures with RLAY calls
Is RLAY a Buy or Sell?
Public buy calls on Relay Therapeutics have outperformed the S&P 500.
On average, public BUY calls on Relay Therapeutics outperformed the S&P 500 by +90.8%.
GotReceipts tracks public buy and sell signals for Relay Therapeutics (RLAY)
and measures outcomes over matched windows.
For this ticker model, performance vs the S&P 500 is based on BUY/ADD calls only.
SELL/REDUCE calls are graded directionally and shown as Correct, Incorrect, or Pending.
That way, you can quickly see whether following public buy calls added value versus simply holding the index.
Do RLAY stock predictions beat the S&P 500?
Yes. Across 4 scored BUY/ADD calls, average return is +99.0% versus +8.2% for the S&P 500, for +90.8% alpha.
Who has the best track record predicting Relay Therapeutics?
Scott Minerd currently ranks #1 on RLAY, with +156.3% average buy return versus +9.1% for the S&P 500 (+147.2% alpha) across 2 scored buy calls.
Is RLAY overvalued or undervalued?
Public prediction track records currently lean bullish on RLAY: buy calls have outperformed the index by +90.8% on average.
Should I follow analyst ratings on RLAY?
Use analyst and public-figure calls as one input, not a standalone signal. GotReceipts shows historical outcomes versus the S&P 500 so you can judge signal quality before acting.